jRCT2051240083进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 168
- 主要终点
- Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 16age old over 至 70age old under（—）
- 性别
- All
入选标准
- •The participant has a body mass index (BMI) within the range 18 to 40 kilograms per meter square (kg/m^2).
- •The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT
- •The participant has greater than or equal to (>=) 4 partial or complete episodes of cataplexy/week (WCR).
- •The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant's cerebrospinal fluid (CSF) orexin (OX)/hypocretin-1 concentration is less than or equal to (=<) 110 picograms per milliliter (pg/mL) [or less than one-third of the mean values obtained in normal participants within the same standardized assay].
排除标准
- •The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
- •The participant: (a) has a history of myocardial infarction; (b) has a history of clinically significant hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or (c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease).
- •The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
- •The participant has a history of cancer in the past 5 years.
- •The participant has a clinically significant history of head injury or head trauma.
- •The participant has a history of epilepsy, seizure, or convulsion.
- •The participant has a history of cerebral ischemia, transient ischemic attack (<5 years from screening), intracranial aneurysm, or arteriovenous malformation.
结局指标
主要结局
Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials
时间窗: Baseline, Week 12
The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session will be recorded. Participants will be required to stay awake in between the 4 sessions.
次要结局
- Change From Baseline to Week 12 in ESS Total Score(Baseline, Week 12)
- Change From Baseline to Week 12 in Mean Number of Lapses on the 3 Psychomotor Vigilance Test (PVT)(Baseline, Week 12)
- Patient Global Impression of Change (PGI-C) Score at Week 12(Week 12)
- Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score(Baseline, Week 12)
- Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores(Baseline, Week 12)
- Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores(Baseline, Week 12)
- Number of Participants with At Least one Treatment-Emergent Adverse Event (TEAE)(Up to 16 weeks)
研究者
相似试验
尚未招募
Unknown
Evaluation of Efficacy Of Takra Dhara And Tagara (Root Extract) In The Management Of Post Covid Anxiety Disorder.CTRI/2023/06/053674Pt Khushilal sharma goverment (autonomous) collage and institute bhopal (mp)
尚未招募
Unknown
Discovering the Mind-Body Benefits of Trataka: A Preliminary Study on Yogas Impact on Eye Health and NeurologyCTRI/2024/07/071218Amrita Vishwa Vidyapeetham
已完成
2 期
To compare the efficacy of Takra Yapana Basti and Takra Kaala Basti in Grahani Roga with special reference to Irritable Bowel SyndromeCTRI/2022/05/042842ational Institute of Ayurveda Jaipur30
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221564TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221774TAKEDA PHARMACEUTICAL COMPANY LTD.